Craig Shimasaki

Craig Shimasaki is an accomplished leader in the biotechnology and precision medicine sectors. As President and CEO of Moleculera Biosciences since September 2011, Craig directs efforts to innovate diagnosis and treatment for chronic disorders linked to immune dysfunction. Additionally, as Co-Founder and Advisor at Izotropic Corp since January 2016, Craig contributes to the advancement of cutting-edge breast cancer detection technology. Craig's academic involvement as Sr. Entrepreneur-in-Residence at the University of Oklahoma helps cultivate the next generation of technology entrepreneurs. With a background as Founder and CEO of BioSource Consulting Group, and previous leadership roles in companies like InterGenetics and ZymeTx, Craig has extensive experience in biotechnology product development and strategic consulting. Craig holds an MBA from the Kellogg School of Management, a PhD in Molecular Biology & Biotechnology from the University of Tulsa, and a BS in Biochemistry from the University of California, Davis.